Research programme: monoclonal antibody therapies - Vaccinex/Five Prime

Drug Profile

Research programme: monoclonal antibody therapies - Vaccinex/Five Prime

Alternative Names: Anti-CXCL13 monoclonal antibody; Anti-VEGF1/2 monoclonal antibody; VX-5; VX-60; VX-70; VX5/5261

Latest Information Update: 14 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaccinex
  • Class Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL13 inhibitors; Immunomodulators; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Autoimmune disorders
  • Discontinued Bacterial infections; Cancer; Viral infections

Most Recent Events

  • 19 Mar 2015 Monoclonal antibody therapies licensed to Five Prime therapeutics worldwide
  • 27 Dec 2014 Preclinical development for Autoimmune disorders is ongoing in USA
  • 05 Nov 2012 Preclinical development for Autoimmune disorders is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top